Last reviewed · How we verify
SGN-00101
At a glance
| Generic name | SGN-00101 |
|---|---|
| Sponsor | Nventa Biopharmaceuticals Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia (PHASE2)
- SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia (PHASE2)
- SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells (PHASE2)
- SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia (PHASE1, PHASE2)
- Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia (PHASE2)
- A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGN-00101 CI brief — competitive landscape report
- SGN-00101 updates RSS · CI watch RSS
- Nventa Biopharmaceuticals Corporation portfolio CI